FORM 10-Q

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

          [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                For the quarterly period ended September 30, 1998

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
       For the transition period from .................to.................

                         Commission file number 33-19583

                            ZEVEX INTERNATIONAL, INC.
               (Exact name of registrant as specified in charter)

          DELAWARE                              87-0462807
(State or other jurisdiction of             (I.R.S.  Employer  
incorporation or organization)              Identification No.)
  

                   4314 ZEVEX Park Lane, Salt Lake City, Utah
           84123 (Address of principal executive offices and zip code)

                                 (801) 264-1001
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
(Former name, former address, and former fiscal year, if changed since 
last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [ X ] No

                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate  by check mark  whether  the  registrant  has filed all  documents  and
reports  required  to be filed by  Sections  12,  13 or 15(d) of the  Securities
Exchange Act of 1934 subsequent to the  distribution of securities  under a plan
confirmed by a court.
Yes  [   ]    No  [   ]    Not Applicable  [ X ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock,  as of the latest  practicable  date. As of November 12, 1998, the
Company had outstanding  3,301,226  shares of common stock, par value $0.001 per
share.

<PAGE>







                                     PART I

                              FINANCIAL INFORMATION

-------------------------------------------------------------------------------

               ITEM 1. FINANCIAL STATEMENTS REQUIRED BY FORM 10-Q
-------------------------------------------------------------------------------

ZEVEX International,  Inc. (the "Company"), files herewith balance sheets of the
Company as of  September  30,  1998,  and  December  31,  1997,  and the related
statements of operations and cash flows for the respective  three month and nine
month  periods  ended  September  30,  1998,  and 1997.  In the  opinion  of the
Company's management,  the financial statements reflect all adjustments,  all of
which  are  normal  recurring  adjustments,  necessary  to  fairly  present  the
financial  condition  of the  Company  for the interim  periods  presented.  The
financial  statements  included  in this  report on Form 10-Q  should be read in
conjunction with the audited  financial  statements of the Company and the notes
thereto  included in the annual  report of the Company on Form 10-K for the year
ended December 31, 1997.
                            

<PAGE>





                                                  

                                                 ZEVEX INTERNATIONAL, INC.
                                                CONSOLIDATED BALANCE SHEETS
                                                          ASSETS

<TABLE>
<CAPTION>
                                                                           Sept 30                        Dec. 31

                                                                            1998                            1997
                                                                           -----                            ----
                                                                         (unaudited)

<S>           <C>                                                        <C>                             <C>    
Current assets:
             Cash and cash equivalents                                     $     2,686                   $  2,260,426
             Restricted cash for sinking
                fund payment on industrial
                 development bond                                               55,059                         76,164
             Accounts receivable                                             2,173,010                      2,095,455
             Inventories                                                     4,333,895                      3,540,591
             Marketable securities                                          11,133,568                     10,403,109
             Deferred income taxes                                             114,933                         82,930
             Prepaid expenses and taxes                                        231,013
                                                                                                               67,307
                                                                        ---------------                ---------------
                              Total current assets                          18,044,164                     18,525,982

             Property and equipment, net                                     4,652,599                      3,933,804
             Patents and trademarks                                            135,350                        122,002
             Deferred acquisition costs                                         28,894                             --
             Other assets
                                                                                   755                            755
                                                                                   ---                            ---
                                                                        $   22,861,762                 $   22,582,543
                                                                        ==============                 ==============

                                         LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
             Accounts payable                                             $  1,243,831                $       640,579
             Other accrued expenses                                            261,732                        264,484
             Income taxes payable                                                   --                        285,403
             Current portion of industrial development bond                    100,000
                                                                                                              100,000
                                                                        ---------------
                              Total current liabilities                      1,605,563                      1,290,466

              Deferred income taxes                                            123,984                        126,380
              Industrial development bond                                    1,800,000                      1,900,000

Stockholders' equity:
             Common stock, $.001 par value: authorized 10,000,000
                shares, issued 3,300,776 and 3,264,326
                 shares, respectively                                            3,301                          3,265
              Additional paid in capital                                    16,825,827                     16,697,203
             Less: Treasury stock                                             (50,790)                             --
             Unrealized (gain)/loss on SAS                                    (53,797)                             --
             Retained earnings
                                                                             2,607,674                      2,565,229
                                                                             ---------                      ---------
                   Total stockholders' equity
                                                                            19,332,215                     19,265,697
                                                                            ----------                     ----------
                                                                        $   22,861,762                 $   22,582,543
                                                                        ==============                 ==============

</TABLE>
                            
                            See accompanying notes.

<PAGE>







                                                  
                                                 ZEVEX INTERNATIONAL, INC.
                                                 STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>

                                                Three months ended                                   Nine months ended
                                                     Sept 30,                                            Sept 30,

                                            1998                  1997                      1998                      1997
                                     -------------------     ----------------        -------------------       --------------------
                                         (unaudited)            (unaudited)              (unaudited)                (unaudited)


<S>                                 <C>                    <C>                       <C>                      <C>   
Revenue:
   Product sales                    $       2,301,498      $       2,437,734         $      7,205,922         $         5,534,205
   Engineering services                        44,645                 59,391                  427,285                     777,285
                                    ------------------     ------------------       ------------------        --------------------
Total revenue                               2,346,143              2,497,125                7,633,207                   6,311,490
Cost of sales                               2,038,200              1,534,365                4,898,227                   3,475,154
                                    ------------------     ------------------       ------------------        --------------------
Gross profit                                  307,943                962,760                2,734,980                   2,836,336

Operating expenses:
  General and administrative                  648,974                473,105                 1,931,996                  1,198,499
  Selling and marketing                       351,508                194,960                   944,197                    528,417
  Research and development                     53,328                 63,749                   209,302                    521,870
                                     -----------------     ------------------       -------------------       --------------------

Total operating expenses                    1,053,810                731,814                 3,085,495                  2,248,786

Operating income (loss)                     (745,867)                230,946                (350,515)                     587,550
Other income (expense):
   Interest income                            158,188                  4,532                  427,252                      66,367
   Interest expense                          (28,517)               (18,918)                 (72,930)                    (56,381)
   Unrealized gain (loss) on                                                                                                
     marketable securities                   (42,963)                  7,812                   31,251                       7,812
Income (loss) before provision       ------------------     ------------------       ------------------        --------------------
for income taxes                            (659,159)                224,372                   35,058                     605,348

Provision for taxes                           239,315               (96,134)                    7,387                   (194,585)
                                    ------------------     ------------------       ------------------        --------------------

Net income (loss)                   $        (419,844)     $         128,238        $           42,445        $            410,763
                                    ==================     ==================       ==================        ====================

Basic net income (loss) per share   $            (.13)     $             .06        $              .01        $                .18
                                                                                                             
                                    ==================     ==================       ==================        ====================
Weighted average shares                                           
   Outstanding                              3,297,688               2,063,826                3,289,312                   2,315,802
                                    ==================     ==================       ==================        ====================
Diluted  net  income   (loss)  per                                                                                       
share                                           (.13)                    .05                       .01                         .17
                                    ==================     ==================       ==================        ====================
Diluted weighted average shares                                                                              
   Outstanding                              3,654,132               2,525,364                3,652,666                   2,455,930
                                    ==================     ==================       ==================        ====================

</TABLE>
                            See accompanying notes.

<PAGE>











                                                 ZEVEX INTERNATIONAL, INC.
                                           CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>      
<CAPTION>
                                                                         Nine months ended
                                                                              Sept 30,
                                                                       1998               1997
  
                                                                  ---------------    ---------------
                                                                    (unaudited)         (unaudited)

<S>                                                               <C>                 <C>  
Cash flows from operating activities
Net income                                                        $        42,445     $      410,763

Adjustments to reconcile  net income to net cash (used in) provided by operating
   activities:
      Depreciation and amortization                                       343,519            177,021
      Benefit for deferred income taxes                                  (34,399)          (152,006)
      Unrealized (gain)/loss on marketable securities                      74,169            (7,812)
      Changes in operating assets and liabilities:
         Decrease  (increase)  in  restricted  cash for  sinking          
         fund payment on industrial development bond                      21,105            (50,306)
         (Increase) decrease in accounts receivable                      (77,555)          (405,490)
         Increase in inventories                                        (793,304)        (1,996,798)
         Increase in deferred offering costs                                   --          (154,694)
         Increase in marketable securities                              (858,425)                 --
         (Increase) decrease in prepaid expenses                        (163,706)             37,744
         (Increase) decrease in other assets                             (28,894)              2,734
         Increase in accounts payable                                     603,252            516,124
         (Increase) decrease in accrued liabilities                       (2,752)            150,706
        (Decrease) increase in income taxes payable                     (285,403)            267,379
                                                                  ---------------    ---------------
Net cash (used in) provided by operating activities                   (1,159,948)        (1,204,635)
Cash flows from investing activities
Purchase of property and equipment                                    (1,055,200)        (2,854,004)
Additions to patents and trademarks                                      (20,462)           (29,584)
                                                                  ---------------    ---------------
Net cash used in investing activities                                 (1,075,662)        (2,883,588)
Cash flows from financing activities
Proceeds from issuance of common stock                                         --          1,498,975
Proceeds from exercise of stock options                                    23,660                 --
Proceeds from exercise of warrants                                        105,000                 --
Purchase of treasury stock                                               (50,790)                 --
Proceeds from bank line of credit                                              --            700,000
Repayment of bank line of credit                                               --           (60,108)
Repayment of industrial development bond                                (100,000)                 --
                                                                  ---------------    ---------------
Net cash (used in) provided by financing activities                      (22,130)          2,138,867
                                                                  ---------------    ---------------
Net decrease in cash and cash equivalents                             (2,257,740)        (1,949,356)
Cash and cash equivalents at beginning of period                        2,260,426          2,085,055
                                                                  ---------------    ---------------
Cash and cash equivalents at end of period                        $         2,686    $       135,699
                                                                  ===============    ===============


</TABLE>

                            See accompanying notes.
<PAGE>





                                             ZEVEX INTERNATIONAL, INC.

                                    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                                September 30, 1998


1.  Summary of Significant Accounting Policies

ZEVEX  (a  Delaware  corporation)  designs  and  manufactures  advanced  medical
devices,  including surgical systems, device components, and sensors for medical
technology companies.  The Company also designs,  manufactures,  and markets its
own medical devices using its proprietary technologies. The Company's design and
manufacturing service customers are medical technology  companies,  who sell the
Company's  systems and devices under private labels or incorporate the Company's
devices into their products.

The  accompanying  financial  statements  have been prepared in accordance  with
generally accepted accounting  principles for interim financial  information and
with the  instructions  to Form 10-Q of  Regulation  S-X.  Accordingly,  certain
information and footnote  disclosures  normally  included in complete  financial
statements have been condensed or omitted.  These financial statements should be
read in conjunction with the financial statements and footnotes thereto included
in the Company's 1997 Annual Report and Form 10-K.

In the  opinion  of  management,  all  adjustments  (consisting  of  normal  and
recurring  adjustments)  considered  necessary for a fair presentation have been
included.  The results of operations  for interim  periods are not indicative of
the results of operations to be expected for a full year.

2. Inventories

Inventories consist of the following:
<TABLE>
<CAPTION>
                                                           September 30           December 31
                                                               1998                   1997
                                                        ------------------    -----------------

                               <S>                     <C>                    <C>    
                               Materials               $         2,226,626    $      2,306,8181
                               Work in progress                  1,833,504            1,044,331
                               Finished Goods,
                                 Including completed
                                 Subassemblies                     273,765              189,442
                                                       -------------------    -----------------
                                                       $         4,333,895    $       3,540,591
                                                       ===================    =================
</TABLE>


3.  Bank Line of Credit

On December 31, 1997, the Company renewed its line of credit  arrangement with a
financial institution for $5 million. The line matures on May 30, 1999. The line
of credit is  collateralized  by accounts  receivable  and  inventory  and bears
interest at the prime rate (8.5% at  September  30,  1998,  and at December  31,
1997).  The  Company's  balance on its line of credit was zero at September  30,
1998 and December 31, 1997. Under the line of credit  agreement,  the Company is
restricted from declaring cash  dividends.  The renewal of the Company's line of
credit resulted in the addition of certain financial covenants.  As of September
30, 1998, the Company was in compliance with these financial covenants.

4.  Stockholders' Equity

Repurchase of Common Stock

On February 4, 1998, the Company  repurchased 6,700 shares of outstanding Common
Stock for $50,790.  The Company anticipates that all the shares repurchased will
be contributed to the Employees' Stock Ownership Plan.

5.  Related Party Transactions

On April 15, 1997, the Company entered into a consulting  agreement with another
company owned by certain  stockholders to provide  services related to strategic
planning, public relations,  financing and potential acquisition of new products
or companies. Under the consulting agreement, the Company paid an initial fee of
$50,000, and must pay $10,000 per month for two years.

In connection  with the secondary  public  offering  completed in November 1997,
certain  stockholders waived their registration  rights on 350,000 warrants.  In
exchange,  the  Company  and the  stockholders  executed a  registration  rights
agreement,  entitling the stockholders to certain demand registration rights for
a period of two years from February 1, 1998.

6.    Comprehensive Income

Effective January 1, 1998, the Company adopted Statement of Financial Accounting
Standards  ("SFAS")  No. 130,  "Reporting  Comprehensive  Income".  SFAS No. 130
requires that all items recognized  under accounting  standards as components of
comprehensive  income be  reported  in an  annual  financial  statement  that is
displayed with the same prominence as other annual  financial  statements.  This
statement  also requires that an entity  classify  items of other  comprehensive
income by their nature in an annual  financial  statement.  Other  comprehensive
income may include  foreign  currency  translation  adjustments,  and unrealized
gains and losses on marketable securities classified as available-for-sale.  For
the first  nine  months  ending  September  30,  1998,  SFAS No.  130 would have
required  the  Company to show  comprehensive  income of $53,797  lower than net
income reported on the Company's financial statements.


<PAGE>


-------------------------------------------------------------------------------

                 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
-------------------------------------------------------------------------------

Results of Operations

The Company's  revenues for the third quarter of 1998  decreased to  $2,301,498,
from $2,437,734 for the third quarter of 1997, a decrease of  approximately  6%.
For the first nine months of 1998,  revenues  increased 21% to  $7,633,207  from
$6,311,490 for the nine months ended 1997.  Although revenues for the nine month
period increased due to overall increases in revenues of contract  manufacturing
and  proprietary  products,  three  months  revenues  are below the prior  years
revenue numbers due to customer delaying orders into the fourth quarter and into
1999.  During the first nine months of 1998, 51% of total revenues,  compared to
67% of total revenues for the first nine months of 1997,  resulted from sales to
three  customers,  all of whom  were  major  customers  in  1997.  Sales  of the
Company's Proprietary Product, the EnteraLite(R) Ambulatory Enteral Feeding Pump
and the enteral feeding  product line,  accounted for  approximately  39% of the
total  revenues  for the third  quarter of 1998,  compared  to 12% for the third
quarter of 1997.

The majority of the Company's products are manufactured for and sold to contract
manufacturing   customers,   who  market  the  final   product.   The  Company's
manufacturing revenue growth depends upon growth in demand for systems,  devices
and instruments manufactured by ZEVEX, and ZEVEX's ability to acquire additional
manufacturing  service  contracts  for these  products  from medical  technology
companies.  ZEVEX's contract manufacturing  customers have complete control over
the marketing and sales of products that ZEVEX  manufactures for them. ZEVEX has
no ability to  increase  demand for  instruments  that it  manufactures  for its
contract  manufacturing  customers.  No assurances can be given that orders from
any  customer  will  increase or remain at current  levels or that they will not
decline.

The Company's gross profit as a percentage of revenues was approximately 14% for
the three months ended  September 30, 1998,  as compared to 39% for 1997.  Gross
profits for nine months ended  September 30, 1998, were 36% for 1998 and 45% for
1997.  Management attributes the decrease in gross profit percentage to a number
of matters,  including  (1) a shift in the revenue mix of its  products to lower
margin items that were sold during the quarter,  (2) delays  experienced  in the
delivery schedules dictated by three of the Company's major customers, where the
Company  normally  experiences  a higher gross margin,  (3)  increased  costs of
engineering staff to execute new engineering and production jobs obtained by the
Company  during the second and third  quarters,  (4) the Company  also  recorded
revenues  related the Nutrition  Medical  acquisition  as well as  non-recurring
engineering  (NRE)  tooling costs on which the Company did not realize any gross
profit and (5) the Company  recognized  costs  associated  with a  reengineering
project to enhance the marketability of a product on a cost-sharing basis with a
major customer.

Selling,  general  and  administrative  expenses  for  the  three  months  ended
September 30, 1998,  increased $332,417,  from $668,065 in 1997 to $1,000,482 in
1998.  For  nine  months  ended  September  30,  1998,   selling,   general  and
administrative  increased  $1,149,277  from  $1,726,916 in 1997 to $2,876,193 in
1998.  Increased  expenses  resulted from the Company's  continuing growth as it
establishes  marketing  channels  for  proprietary  products.  The Company had a
one-time  expense  related to its application and listing on the NASDAQ National
Market,  also increased  legal,  accounting,  general  consulting and public and
investor  relations  increased  general  expenses.  Expanded sales and marketing
efforts increased  staffing,  travel,  advertising and  administrative  expenses
related to the Company's  proprietary  clinical nutrition delivery product line.
The  Company  also had an increase in  expenses  related to  employees,  such as
insurance,  taxes, and pension  benefits.  The Company believes that general and
administrative   expenses  in  1998  as  related  to  sales  will   continue  at
approximately the same percentage as in the previous two years.

Research and development  expenses vary from quarter to quarter depending on the
number and nature of pending research and development projects and their various
stages of completion.  For the three months ended  September 30, 1998,  research
and development  expenses were $53,328 in 1998, compared to $63,749 in 1997. For
nine months ended  September 30, 1998,  research and  development  expenses were
$209,302 for 1998 and $521,870 for 1997. Significant fluctuations experienced in
research  and  development  are  due to the  timing  of the  Company's  research
projects.  Expenses  incurred  during the third  quarter were for the  continued
development  of new  applications  of the Company's  ultrasound  technology  and
proprietary products.  Management believes investing in research and development
will serve the Company's  future well,  and intends to continue this  investment
for the foreseeable future.  Research and development  expenses will continue at
approximately the same percentage as in the previous two years.

For the three  months  ended  September  30,  1998 the Company had a net loss of
$419,844,  18% of revenues compared to $128,238 net income, for the three months
ended September 30, 1997, or approximately 5.1% of revenues.  Net income for the
nine months ended  September 30, 1998,  decreased to $42,445,  0.5% of revenues,
from  $410,763,  6.5% of 1997  revenues.  The decrease in net income  during the
third quarter of 1998, as compared to the third quarter of 1997, is  principally
due to the lower margin product sold,  increased  engineering  staff and related
expenses as discussed above.

As of  September  30,  1998,  the  Company's  backlog  of  customer  orders  was
$6,327,000,  as  compared  to  $7,726,000  on  September  30,  1997.  Management
estimates that  approximately 60% of the backlog will be shipped before December
31, 1998. The Company's  backlog is for contract  manufacturing  only and can be
drastically  affected  by the timing of annual or  semi-annual  purchase  orders
placed by its customers.

Liquidity and Capital Resources

During the three months and nine months ended  September  30, 1998,  the Company
produced  a net  loss of  $419,844  and net  income  of  $42,445,  respectively,
compared  to net incomes of $56,987 and  $282,525,  respectively,  for the three
months and nine months ended  September 30, 1997.  Cash  decreased by $2,257,740
for the nine months ending September 30, 1998, as the Company  continued to fund
an increase in accounts  receivable  and  inventories,  as well as  purchases of
property, plant and equipment.

The  Company's  investment in property,  patents from new research,  production,
test equipment and tooling was  $1,075,662  for the nine months ended  September
30, 1998,  compared to $2,883,588 in 1997. The Company paid $580,000 to purchase
a parcel of land,  approximately 3.47 acres, to the north of its facility. Total
expenditures  for  equipment of $476,214  were  primarily  due to upgrading  the
Company's research, design and engineering capabilities.  The Company expects to
spend   approximately   $100,000  for  the  remainder  of  1998  for  additional
manufacturing equipment, as well as for normal replacement of old equipment. The
Company  also  anticipates  approximately  $250,000 of  additional  research and
development expenses during 1998.

The Company's working capital at September 30, 1998 was $16,438,601, compared to
$3,587,841 at September 30, 1997.  The increase in working  capital is primarily
due to the secondary  offering that was completed in November 1997, as described
in the  Stockholders'  Equity  section  of the Notes to  Consolidated  Financial
Statements in the Company's 1997 Annual Report.  The portion of working  capital
represented  by cash at such  dates was $2,686 and  $135,699  respectively.  The
Company  has  $10,496,008  in short term,  investment  grade,  interest  bearing
investments at September 30, 1998. The Company uses substantial  portions of its
cash  from  time  to  time  to  fund  its  operations,  including  increases  in
inventories,  accounts receivable and work in process in connection with various
customer orders.



<PAGE>


Cautionary Statement for Purposes of "Safe Harbor Provisions" of the Private
Securities Litigation Reform Act of 1995

When used in this report, the words "estimate," "believe," "project" and similar
expressions,  together with other  discussion  of future trends or results,  are
intended to identify  forward-looking  statements  within the meaning of Section
27A of the Securities Act of 1933, as amended (the "Securities Act") and Section
21E of the  Securities  Exchange Act of 1934, as amended (the  "Exchange  Act").
Such statements are subject to certain risks and uncertainties,  including those
discussed below, that could cause actual results to differ materially from those
projected.  These  forward-looking  statements speak only as of the date hereof.
All of these  forward-looking  statements are based on estimates and assumptions
made by management of the Company, which although believed to be reasonable, are
inherently uncertain and difficult to predict.  Therefore, undue reliance should
not be placed upon such  estimates.  There can be no assurance that the benefits
anticipated in these forward-looking  statements will be achieved. The following
important  factors,  among  others,  could  cause the Company not to achieve the
benefits  contemplated  herein,  or  otherwise  cause the  Company's  results of
operations  to be  adversely  affected  in  future  periods:  (i)  continued  or
increased competitive pressures from existing competitors and new entrants; (ii)
unanticipated  costs related to the Company's  growth and operating  strategies;
(iii) loss or retirement of key members of management; (iv) increase in interest
rates of the Company's  cost of borrowing,  or a default under any material debt
agreement;  (vi) prolonged labor disruption;  (viii) deterioration in general of
regional  economic  conditions;  (ix) adverse  state or federal  legislation  or
regulation  that  increases  the cost of  compliance,  or adverse  findings by a
regulator  with  respect  to  existing  operations;  (x) loss of  customers;(xi)
adverse  determinations in connection with pending or future litigation or other
material  claims and judgments  against the Company;  (xii) inability to achieve
future sales; and (xiii) the  unavailability of funds for capital  expenditures.
Many of such factors are beyond the control of the Company.  Please refer to the
Company's  SEC Form 10-K for its  fiscal  year  ended  December  31,  1997,  for
additional cautionary statements.


<PAGE>


                                     PART II


Item 1.  Legal Proceedings - None.
Item 2.  Changes in Securities and Use of Proceeds - None.
Item 3.  Defaults upon Senior Securities - None.
Item 4.  Submission of Matters to a Vote of Security Holders - None.
Item 5.  Other Information

On July 28, 1998, ZEVEX International,  Inc.'s wholly-owned  subsidiary,  ZEVEX,
Inc.  signed an agreement to acquire the product  rights to the enteral  feeding
pumps, delivery sets and feeding tubes of Minneapolis, Minnesota-based Nutrition
Medical Inc.  Enteral  pumps  deliver  nutrition to patients  requiring  feeding
through the intestines or stomach. Total sales of these products for the past 12
months ending June 30, 1998 were approximately $2 million. Consideration for the
transaction will be approximately  $1.22 million,  comprised of $500,000 in cash
and 115,000  shares of ZEVEX  International  common stock,  currently  valued at
$704,375.  The  acquisition  is subject to approval by  Nutrition  Medical  Inc.
shareholders,   which  is  expected  in  the  fourth  quarter  1998.   Effective
immediately,  ZEVEX has entered into an exclusive  marketing agreement for these
product lines. The marketing agreement will be in effect until the completion of
the acquisition.

On November 6, 1998, ZEVEX International, Inc.'s wholly-owned subsidiary, ZEVEX,
Inc.  executed  letters of intent to acquire two companies,  Aborn  Electronics,
Inc. and J-Tech Medical  Industries,  Inc. Aborn is a manufacturer and developer
of optic sensors and custom  computer  chips used in both medical and industrial
devices.   J-Tech  Medical  Industries  manufactures  and  markets  computerized
musculoskeletal  evaluation  products,  which measure  isolated muscle strength,
joint ranges of motion and sensation during physical therapy.  Consideration for
the  transactions  will be  approximately  $12.35  million,  comprised  of cash,
convertible debentures and earn-outs.  These two acquisitions are subject to the
execution of definitive  agreements and further due diligence,  and are expected
to close in the fourth quarter 1998

Item 6. Exhibits and Reports on Form 8-K - None.


-------------------------------------------------------------------------------

                                   SIGNATURES
-------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


ZEVEX INTERNATIONAL, INC.


Dated:  November 13, 1998
                     By   /s/ Dean G. Constantine
                      Dean G. Constantine, President


                     By   /s/ Phillip L. McStotts
                      Phillip L. McStotts, Secretary
                      (Principal Financial Officer)